A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer
Intralesional TVEC demonstrated promising efficacy and tolerability as a minimally invasive treatment for low to intermediate risk cSCC with potential to reduce subsequent incidence rates.
Authors
- Clara Curiel‐Lewandrowski (ORCID: https://orcid.org/0000-0001-8982-6252)
- Denise J. Roe (ORCID: https://orcid.org/0000-0001-6989-6579)
- Haiyan Cui (ORCID: https://orcid.org/0000-0003-4969-4835)
- S Sundararajan
- Delaney Stratton (ORCID: https://orcid.org/0000-0002-3285-345X)
- Amy C. Adams
Institutions
- University of Arizona (US)
- University of Phoenix (US)
- Arizona Science Center (US)
- Hanby Environmental (United States) (US)
- Arizona Oncology (US)
- University of Arizona Cancer Center
- Phoenix College (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.jaad.2025.11.026
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00